Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
NOTE: If you attended the live CE activity titled "Facing the Challenges of Invasive Fungal Infections: Clinical Updates & Best Practices" that was held on December 7, 2016 during the 51st ASHP Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-16-332-L01-P), you are ineligible to also receive CE credit for this home-study activity.
Invasive fungal infections (IFIs) are life-threatening conditions that require astute diagnosis and management to mitigate the high associated morbidity and mortality risks. IFIs are also associated with a high economic burden, owing to prolonged hospitalization, the need for intensive supportive care, and the use of costly new antifungal agents. Opportunistic IFIs occur predominantly in immunocompromised patients, and the incidence of these infections is on a steady increase, as more and more patients undergo surgical procedures, transplantation, or cancer treatment and are receiving immunosuppressive therapies. Several classes of antifungal agents can be used to treat these invasive infections, but some fungi have developed resistance and no longer respond to standard antifungals intended to eradicate them.
New therapies offer the potential to improve outcomes for patients with IFIs, but early diagnosis remains a critical component in the effective management of these deadly infections. Clinicians should be aggressive in seeking a diagnosis in patients who are suspected of having an IFI, and the use of available diagnostic tools can improve rates of detection.
As medication experts, pharmacists in health-system settings need to assess antifungal use as part of their antimicrobial stewardship programs. This activity will review emerging data and strategies on the diagnosis and pharmacologic management of IFIs, and will use interdisciplinary case examples to demonstrate the clinical application of these principles.
The target audience for this activity includes pharmacists and infectious-disease pharmacists. Upon completion of this activity, participants will be able to:
Douglas Slain, PharmD, BCPS, FCCP, FASHP (Chair)
Infectious Diseases Clinical Specialist
West Virginia University
Morgantown, West Virginia
Melissa D. Johnson, PharmD, MHS, AAHIVP
Associate Professor of Medicine
Division of Infectious Diseases & International Health
Duke University Medical Center
Liaison Clinical Pharmacist
Duke Antimicrobial Stewardship Outreach Network
Durham, North Carolina
Ryan K. Shields, PharmD, MS
Assistant Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Johnson is an Author for UpToDate and a Principal Investigator for Charles River Laboratories. Dr. Shields is a Consultant for Cidara and an Investigator for Merck and Theravance. Dr. Slain has no relevant commercial or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 01-16-2017
Expiration Date: 01-16-2018
This CE activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists (SIDP). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-17-003-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 1-16-17). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This CE activity is supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.